Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its ongoing Phase 1 trial for ADI-001.
Patient enrollment for these cohorts is set to begin in the first quarter of 2025. ADI-001's clinical development now targets six autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
Adicet plans to report initial data from its Phase 1 trial in the first half of 2025.
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Redwire partners with Bristol Myers Squibb for space-based drug research
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Merck acquires CN201 from Curon Biopharmaceutical
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases